Advertisement

Topics

NICE approval would let Novartis' Kisqali steal a march on Ibrance

06:46 EDT 24 Aug 2017 | pharmaphorum

Novartis' breast cancer treatment Kisqali has gained final EU approval today - and the company is confident it can follow this with a swift reimbursement recommendation from the UK's NICE. Kisqali (ribociclib) is a rival to Pfizer's Ibrance, and b...

Original Article: NICE approval would let Novartis' Kisqali steal a march on Ibrance

NEXT ARTICLE

More From BioPortfolio on "NICE approval would let Novartis' Kisqali steal a march on Ibrance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...